University of Hawaiʻi Cancer Center researcher Stephanie Si Lim was selected as a member of the Association of American Cancer Institutes Physician Clinical Leadership Initiative Steering Committee.
The committee, consisting of cancer center researchers across the nation, seeks to identify roadblocks in cancer care, ensure quality of services, provide faculty career development and enhance ways of disseminating information across cancer centers.
As a physician-scientist, Si Lim will offer and share insights into overcoming barriers and challenges within cancer centers by establishing better practice guidelines that encompass finance, budgeting and clinical trials access.
“It is a great honor to be selected as I can be a part of the leadership team that helps define practices that will maximize efficient and effective operation within cancer centers,” said Si Lim. “Particularly important to Hawaiʻi and the Pacific Islands will be finding ways to promote clinical trial enrollment so we can continue to offer the best cancer therapies available to all our patients within our community.”
During the COVID-19 pandemic, patient and resident participation in clinical trials at the UH Cancer Center and across the nation began to decline. A key goal of Si Lim is to identify ways to increase clinical trial enrollment. The UH Cancer Center currently offers access to more than 80 clinical trials in Hawaiʻi and the Pacific.
Si Lim, who also is a pediatric hematologist oncologist at Kapiʻolani Medical Center for Women & Children, recently brought Chimeric Antigen Receptor T-cell therapy to Hawaiʻi. She is leading the initiative to build a broader cellular immunotherapy program.
- Related UH News story: Broadening access to cancer fighting therapy led by UH researcher, July 26, 2022